Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 85


A cell proliferation and chromosomal instability signature in anaplastic thyroid carcinoma.

Salvatore G, Nappi TC, Salerno P, Jiang Y, Garbi C, Ugolini C, Miccoli P, Basolo F, Castellone MD, Cirafici AM, Melillo RM, Fusco A, Bittner ML, Santoro M.

Cancer Res. 2007 Nov 1;67(21):10148-58.


Identification of Polo-like kinase 1 as a potential therapeutic target in anaplastic thyroid carcinoma.

Nappi TC, Salerno P, Zitzelsberger H, Carlomagno F, Salvatore G, Santoro M.

Cancer Res. 2009 Mar 1;69(5):1916-23. doi: 10.1158/0008-5472.CAN-08-1693. Epub 2009 Feb 17.


Suppression of Polo like kinase 1 (PLK1) by p21(Waf1) mediates the p53-dependent prevention of caspase-independent mitotic death.

Lin YC, Sun SH, Wang FF.

Cell Signal. 2011 Nov;23(11):1816-23. doi: 10.1016/j.cellsig.2011.06.016. Epub 2011 Jun 29.


The PLK1 inhibitor GSK461364A is effective in poorly differentiated and anaplastic thyroid carcinoma cells, independent of the nature of their driver mutations.

Russo MA, Kang KS, Di Cristofano A.

Thyroid. 2013 Oct;23(10):1284-93. doi: 10.1089/thy.2013.0037. Epub 2013 Jul 25.


Nitric oxide down-regulates polo-like kinase 1 through a proximal promoter cell cycle gene homology region.

Zhang J, Wang S, Kern S, Cui X, Danner RL.

J Biol Chem. 2007 Jan 12;282(2):1003-9. Epub 2006 Nov 22.


Polo-like kinase 1 (Plk1) inhibits p53 function by physical interaction and phosphorylation.

Ando K, Ozaki T, Yamamoto H, Furuya K, Hosoda M, Hayashi S, Fukuzawa M, Nakagawara A.

J Biol Chem. 2004 Jun 11;279(24):25549-61. Epub 2004 Mar 15.


Expression of bcl-2, c-erbB-2, p53, and p21 (waf1-cip1) protein in thyroid carcinomas.

Soda G, Antonaci A, Bosco D, Nardoni S, Melis M.

J Exp Clin Cancer Res. 1999 Sep;18(3):363-7.


Normal cells, but not cancer cells, survive severe Plk1 depletion.

Liu X, Lei M, Erikson RL.

Mol Cell Biol. 2006 Mar;26(6):2093-108.


Polo-like kinase 1 overexpression is an early event in the progression of papillary carcinoma.

Ito Y, Miyoshi E, Sasaki N, Kakudo K, Yoshida H, Tomoda C, Uruno T, Takamura Y, Miya A, Kobayashi K, Matsuzuka F, Matsuura N, Kuma K, Miyauchi A.

Br J Cancer. 2004 Jan 26;90(2):414-8.


Genistein-induced neuronal apoptosis and G2/M cell cycle arrest is associated with MDC1 up-regulation and PLK1 down-regulation.

Ismail IA, Kang KS, Lee HA, Kim JW, Sohn YK.

Eur J Pharmacol. 2007 Dec 1;575(1-3):12-20. Epub 2007 Jul 28.


Combined gene expression profiling and RNAi screening in clear cell renal cell carcinoma identify PLK1 and other therapeutic kinase targets.

Ding Y, Huang D, Zhang Z, Smith J, Petillo D, Looyenga BD, Feenstra K, Mackeigan JP, Furge KA, Teh BT.

Cancer Res. 2011 Aug 1;71(15):5225-34. doi: 10.1158/0008-5472.CAN-11-0076. Epub 2011 Jun 3.


A single cell cycle genes homology region (CHR) controls cell cycle-dependent transcription of the cdc25C phosphatase gene and is able to cooperate with E2F or Sp1/3 sites.

Haugwitz U, Wasner M, Wiedmann M, Spiesbach K, Rother K, Mössner J, Engeland K.

Nucleic Acids Res. 2002 May 1;30(9):1967-76.


Oncogenic effect of Polo-like kinase 1 expression in human gastric carcinomas.

Jang YJ, Kim YS, Kim WH.

Int J Oncol. 2006 Sep;29(3):589-94.


A comparative study of cell cycle mediator protein expression patterns in anaplastic and papillary thyroid carcinoma.

Evans JJ, Crist HS, Durvesh S, Bruggeman RD, Goldenberg D.

Cancer Biol Ther. 2012 Jul;13(9):776-81. Epub 2012 Jun 12.


Induction of tetraploidy through loss of p53 and upregulation of Plk1 by human papillomavirus type-16 E6.

Incassati A, Patel D, McCance DJ.

Oncogene. 2006 Apr 20;25(17):2444-51.


Plk1 regulates liver tumor cell death by phosphorylation of TAp63.

Komatsu S, Takenobu H, Ozaki T, Ando K, Koida N, Suenaga Y, Ichikawa T, Hishiki T, Chiba T, Iwama A, Yoshida H, Ohnuma N, Nakagawara A, Kamijo T.

Oncogene. 2009 Oct 15;28(41):3631-41. doi: 10.1038/onc.2009.216. Epub 2009 Aug 10.


FOXA1 is a potential oncogene in anaplastic thyroid carcinoma.

Nucera C, Eeckhoute J, Finn S, Carroll JS, Ligon AH, Priolo C, Fadda G, Toner M, Sheils O, Attard M, Pontecorvi A, Nose V, Loda M, Brown M.

Clin Cancer Res. 2009 Jun 1;15(11):3680-9. doi: 10.1158/1078-0432.CCR-08-3155. Epub 2009 May 26.


PLK1 Is transcriptionally activated by NF-κB during cell detachment and enhances anoikis resistance through inhibiting β-catenin degradation in esophageal squamous cell carcinoma.

Lin DC, Zhang Y, Pan QJ, Yang H, Shi ZZ, Xie ZH, Wang BS, Hao JJ, Zhang TT, Xu X, Zhan QM, Wang MR.

Clin Cancer Res. 2011 Jul 1;17(13):4285-95. doi: 10.1158/1078-0432.CCR-10-3236. Epub 2011 May 24.

Supplemental Content

Support Center